Supplementary Materials

Supplementary Material for:

Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma

Micol Ravà, Aleco D'Andrea, Paola Nicoli, Ilaria Gritti, Giulio Donati, Mirko Doni, Marco Giorgio, Daniela Olivero, Bruno Amati*

*Corresponding author. Email: bruno.amati{at}

Published 31 January 2018, Sci. Transl. Med. 10, eaan8723 (2018)
DOI: 10.1126/scitranslmed.aan8723

This PDF file includes:

  • Fig. S1. Response of mouse Eμ-myc/BCL2 lymphomas to tigecycline and venetoclax.
  • Fig. S2. Synergistic effects of tigecycline and venetoclax against human DHL cell lines.
  • Fig. S3. Similar effects of tigecycline, doxycycline, and tetracycline in DHL cells.
  • Fig. S4. Short-term effects of tigecycline and venetoclax in SU-DHL-6 tumors.
  • Fig. S5. Reactive liver lesions caused by intraperitoneal delivery of tigecycline.
  • Fig. S6. Toxicology of tigecycline and venetoclax drug combination studies in vivo.
  • Fig. S7. Whole-body imaging of PDX-derived tumors treated with tigecycline and/or venetoclax.
  • Fig. S8. Kaplan-Meier representation of disease-free survival in PDX-recipient mice.
  • Fig. S9. Effect of rituximab with tigecycline and/or venetoclax on DHL xenografts.
  • Fig. S10. Whole-body imaging of PDX-derived tumors treated with rituximab, tigecycline, and/or venetoclax.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Primary data.